Summary Anti-tumour effector cells were generated through 4 days culture of normal C57BL/6 splenocytes in a medium containing concanavalin A supernatant and then fractionated with Dolichos biflorus lectin (DBA) into DBA+ (agglutinable with DBA) and DBA-(non-agglutinable with DBA) cells. The DBA-cells, infused intravenously into mice together with B16 melanoma cells, or adoptively transfered into mice 3 days after the injection of B16 cells, caused a marked decrease in the number of lung nodules, while the DBA + cells exerted no effect. On the other hand, the DBA + cells exhibited higher cytolytic activity in vitro than the DBA-cells in short-term 5'Cr-release assays. Then, we analysed the mechanism of the strong anti-tumour activity of DBAcells in vivo. We found that DBA-cells showed higher reponse to recombinant interleukin-2 (rlL-2) than DBA+ cells and proliferated very well with a small amount of IL-2. In addition, DBA-cells adhered more strongly to lung endothelial cells than DBA+ cells in response to rlL-l or rTNF. Furthermore, DBA-cells produced larger amounts of macrophage activating factor (MAF) including IFN-'y when cultured with B16 melanoma. Taken together, our results show that DBA-cells are effective in reducing experimental pulmonary metastases not only by the direct lytic activity but also by the indirect killing activity through the activated macrophage.
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In previous studies, we fractionated splenocytes of X5563 tumour-bearing mice, which had been treated with the supernatant of mouse splenocytes cultured with concanavalin A (Con A sup), with Dolichos biflorus lectin (DBA) into DBA + (agglutinable with DBA) and DBA-(non-agglutinable with DBA) cells and demonstrated that DBA-cells showed strong antitumour activity against X5563 in vivo when injected into mice together with human recombinant interleukin-2 (rIL-2), despite the fact that DBA' cells showed stronger cytolytic activity in vitro than DBA-cells (Okada et al., 1986) .
Recent studies have shown that murine splenocytes or human peripheral blood lymphocytes, on incubation in vitro in the presence of IL-2, acquire the ability to lyse a variety of fresh syngeneic murine and autologous human tumour cells in short-term 5'Cr-release assays. These lymphokine-activated killer (LAK) cells are distinct from natural killer (NK) cells or classical cytotoxic T-cells, and are lytic toward allogenic tumour target cells from murine and human sources as well (Grimm et al., 1982 Rosenstein et al., 1984) .
The adoptive transfer of syngeneic LAK cells in conjunction with the systemic administration of rIL-2 reduced the number of pulmonary and hepatic metastases from murine tumours of different histological types (Lafreniere & Rosenberg, 1985a, b; Mule et al., 1984 Mule et al., , 1985 Mule et al., , 1986a Moshe et al., 1986) .
In the present study, we examined the ability of Con A sup-cultured cells, separated with the use of DBA, to reduce the number of experimental pulmonary metastases in a murine model. Then we investigated the mechanism of antitumour activity of DBA-cells in vivo, in terms of the following characteristics of the effector cells: (1) the proliferation rate in response to rIL-2; (2) the lymphokine producing activity; (3) the binding activity to lung endothelial cells under inflammatory conditions.
Materials and methods
Mice Female C57BL/6, BALB/c and DBA/2 mice (7-12 weeks old) were used in these experiments. The mice were obtained from Charles River Japan Inc. (Kanagawa, Japan).
Tumours
The B16 melanoma tumour line used was of C57BL/6 origin. B16 tumour cells (I x 105) were injected into the tail veins of C57BL/6 mice. After 21-23 days, the animals were killed, their lungs harvested and then the pulmonary nodules counted. Complete enumeration of the experimental metastases was possible because they comprised black nodules on the surface of the lungs. This tumour line was maintained in RPMI-1640 medium supplemented with 10% heatinactivated fetal calf serum (FCS; MA Bioproducts, Walkersville, MD, USA), 20 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid (HEPES), 2 mM glutamine (Wako Pure Chemical Co., Tokyo, Japan), penicillin (100 U-1'; Sigma Chemical Co., St Louis, MO, USA) and streptomycin (100 fig ml-'; Sigma Chemical Co.). Cultured cells were harvested by treatment with Ca2 + /Mg2 +-free Hank's balanced salt solution containing 0.05% trypsin and 0.02% disodium EDTA at 37'C for 5 min. RPMI-1640 medium containing 10% FCS was added to stop the reaction and then the cells were washed twice with RPMI-1640 medium. Cells were resuspended in the appropriate buffer at the appropriate concentration and used for inoculation. 242 T. OKADA et al.
(100pgmlm') (complete medium) containing Con A (2.5 g ml1') and 2.5% FCS. Then the supernatant was filtered through a membrane filter (pore size, 0.2 tsm; Toyo Roshi, Tokyo, Japan), and stored at -20C until use. The supernatant (Con A sup) thus prepared was generally used for the cell cultures.
Assay for IL-2 activity The IL-2 activity present in the Con A sup prepared by the method described above was determined in a standard microassay method based upon the IL-2 dependent proliferation of CTLL-2 cells (Gillis et al., 1978) , which were cultured in flat-bottomed microplate wells in complete medium (200 jsl) . Each well contained 104 CTLL cells together with log 2 dilution (ranging from 3% to 50% by volume) of the Con A sup. As a positive control, rIL-2 (Takeda Chemical Industries Ltd, Osaka, Japan) was added to the cultures. The activity of the rIL-2 preparation was defined as I U per 27 ng by the supplier. After a 24 h incubation (37°C in a humidified atmosphere of 5% CO2 in air) the microplate wells were pulsed with 0.5 pCi of 3H-TdR (15 Ci mmol-l; New England Nuclear, Boston, MA, USA). Cultures were harvested 6 h later onto glass fibre filter strips and 3H-TdR incorporation was determined with a liquid scintillation counter (LCS-700, Aloka, Tokyo, Japan).
Generation of cytotoxic effector cells
The spleens were removed from female C57BL/6 mice and then teased into a single cell suspension in RPMI-1640 Separation of cytotoxic effector cells through the use of the DBA The Con A-sup-cultured cytotoxic effector cells were separated through rosetting with DBA-coupled sheep red blood cells (SRBC) followed by Ficoll-Urografin density gradient centrifugation as previously described (Okada et al., 1986) . The DBA+ (rosette-forming cells with DBA-SRBC) and DBA-(non-rosette-forming cells with DBA-SRBC) cells were treated with modified Gey's BSS, to lyse SRBC, and then washed with a solution of 50 mM N-acetyl-D-galactosamine, a haptenic sugar for the DBA lectin.
5'Cr-release of cytotoxicity assay The 4 h chromium release assay was used in this study.
Varying numbers of effector cells (100 slI) and 104 viable 51Cr-labelled tumour target cells were plated in the wells of 96-well round bottomed microplated (Sumitomo, Osaka, Japan) in a total volume of 200 LI. The plates were centrifuged at 100g for I min and then incubated at 37°C under 5% CO2 in air for 4 h. Then the plates were centrifuged again at 250 g for 5 min, and the supernatants (100 p1) were harvested and subjected to radioactivity counting with a gamma-counter (ARC-500 auto well gamma system; Aloka, Tokyo, Japan). The spontaneous release was determined by incubating 5'Cr-labelled target cells alone, and the maximum release was determined after lysing the target cells in 0.4 N NaOH. When staining cells for analysis of L3T4 antigens, the first incubation was performed with monoclonal anti-L3T4 (final dilution, 1/10; Becton) and the second with FITC-conjugated anti-rat kappa (final dilution, 1/50; Becton).
When staining cells for analysis of the affinity of the DBA lectin, the first incubation was performed with biotinyl DBA (final dilution, 15 gg ml-'; Vector) for 30 min, and the second with FITC-conjugated avidin (final dilution 1/100; Vector Lab.).
In the case of staining cells for analysis of asialo GM, (AGMI), the first incubation was performed with anti-AGM, (final dilution, 1/250; Wako Chemical Co., Osaka, Japan) and the second with FITC-goat anti-rabbit Ig (IgA + IgG + IgM) (final dilution, 1/100; Cappel, West Chester, PA, USA).
We examined the expression of T cell receptor on effector cells by staining them with an anti-T3 monoclonal antibody 145-2C1 1 (Leo et al., 1987 ) (final dilution, 1/20) for the first incubation, and with FITC-goat anti-hamster IgG (final dilution, 1/100; EY Laboratory, San Mateo, CA, USA) for the second. The expression of NKI. on effector cells was examined by staining them with the supernatant of antiNKl.1-producing PK136 hybridoma (Koo & Peppard, 1984) (final dilution, 1/10) for the first incubation, and with FITC goat anti-mouse IgG (Fc fragment specific, final dilution, 1/50; Cappel) for the second.
Staining of cells for analysis for Thyl.2 was performed by first incubating the cells on ice for 1 h with FITC-conjugated anti-mouse Thyl .2 (final dilution, 1/100; Bio-Yeda, Rehovot, Israel), and then, each lot of cells was analysed using a cell sorter (FCS-1; Japan Spectroscopic Co. Ltd, Tokyo, Japan) after washing three times with PBS-NaN3-BSA.
Binding to endothelial cells (EC) EC monolayer adhesion assay (Damle et al., 1987; Cavender et al., 1987a, b) Figure 2 , the DBA + cells also showed significantly stronger cytolytic activity than the DBA-cells in these cases (E/T = 15; Student's t test, P<0.00l).
In vivo anti-tumour activity of DBA-separated cells To evaluate the anti-tumour efficacy of the DBA-separated cells in vivo, DBA-separated cells (4 x 106) were intravenously injected into C57BL/6 mice together with B16 cells (1 x 105) injection (Winn assay). Figure 3a shows the number of experimental pulmonary metastases determined for each group, in a blind fashion. (Cavender et al., 1987a, b) . In vitro study showed that the pretreatment of endothelial cells with rIL-1 or rTNF augments their adhesion to lymphocytes or IL-2 cultured lymphocytes (Damle et al., 1987; Cavender et al., 1987a, b) , and the lymphocyte-binding reached a plateau at the concentration of I U ml-' of IL-1 (Pober et al., 1986) or TNF (Cavender et al., 1987b Twenty-three days after the tumour cell injection, the number of lung metastases was determined.
first examined the response of separated cells to rIL-2. As shown in Figure 5 , DBA-cells were more responsive to rIL-2 than DBA + cells. These results were quite reproducible in several independent experiments. Since there seems to be very little IL-2 in vivo, the high responsiveness of DBA-cells to IL-2 even in very low concentrations of the factor may be very advantageous for the cells to proliferate in vivo.
Indirect anti-tumour effect through the elaboration of lymphokines Furthermore, since there is a possibilty that DBA-cells act indirectly through activation of other types of cells by secretion of certain lymphokines, experiments were performed to find out whether DBA-separated cells secrete the macrophage activating factor (MAF). DBA-separated or unseparated cells were cultured with the B16 melanoma in the presence of rIL-2 for several days. Then the supernatants were tested for MAF activity. MAF activity was estimated by the induction of cytolytic activity of proteose peptone-induced macrophages (Mqp) against P815 cells. The culture medium used in these experiments contained polymyxin B to block the effect of contaminating LPS, if any. As shown in Figure 7 , DBAcells produced a large amount of MAF when cultured with the B16 melanoma in the presence of rIL-2 for 3 days. On the other hand, DBA + or unseparated cells produced only a detectable level of MAF. In the absence of the B16 melanoma, neither DBA+ nor DBA-cells released MAF, and no MAF was produced from B16 cells alone under these cultures conditions. If rIL-2 was not added to the culture medium, all the effector cells died in 2 days and no MAF was secreted. These results suggested that DBA-cells were stimulated by the B16 melanoma in the presence of rIL-2 and secreted MAF in the culture medium. The production of MAF was detectable on day 2 and reached a peak on day 3. After 4 or 5 days, the viability of effector cells decreased and no MAF activity was detected.
We then examined characteristics of the MAF activity in DBA-supernatant. As shown in Figure 8 , neither LPS nor murine rIFN-y showed MAF activity by themselves, but showed MAF activity synergistically. 
Discussion
In this study, the DBA-cells separated from Con A-supcultured mouse splenocytes were found to show high inhibitory activity toward experimental metastasis when injected together with B16 tumour cells (Figure 3a) and also when adoptively transferred 3 days later after inoculation of the tumour cells (Figure 3b) . Furthermore, the cell number that was sufficient for reducing the number of metastatic lung nodules was markedly less than that employed for the therapy involving LAK cells by other investigators. On the other hand, DBA+ cells showed stronger cytolytic activity in vitro than DBA-cells (Figure 1 ), but they showed much weaker activity in vivo (Figure 3) .
The dissociation of the cells responsible for the in vitro cytolytic effect and the in vivo anti-tumour effect, respectively, was also demonstrated by other investigators. Mule et al. (1986b) reported that, in combination with the systemic administration of rIL-2, LAK cells which had been treated with anti-Thyl and complement, and which were not cytolytic in vitro assays, remained as effective as untreated cytolytic LAK cells upon adoptive transfer in reducing the number of established pulmonary metastases. Shu et al. (1987) also showed that although spleen cells, which had been sensitised in vitro with viable tumour cells and IL-2, from normal C57BL/6 mice did not exhibit anti-tumour activity in vivo, they displayed non-specific LAK-like cytotoxic activity in vitro. They therefore concluded that it is unlikely that the in vitro cytotoxic activity was directly related to the in vivo anti-tumour effect. We investigated some properties of DBA-separated cells in order to examine the reasons why DBA- (Figure 6 ). However, the binding of DBA + cells to EC was not enhanced by this treatment. These results suggest that DBA-cells effectively bind to the lung EC in situ of tumour tissue where the inflammatory lymphokines are released, then infiltrate into the tumour site and attack the tumour cells.
Since the anti-tumour activity of activated M.p in vivo is well known (Higuchi et al., 1988) , we tested the DBAseparated cells for their ability to generate M<p activating factor (MAF). It was found that DBA-cells secreted Mqp activating factor when cultured with B16 cells (Figure 7) , and this MAF activity mainly depended upon IFN-' (Figure 8 Murine rIFN-y (20 U ml-), LPS (0.1 jig ml-') was added to the assay medium of MAF activity. Anti-IFN-y (having activity of neutralising i04 U IFN) was added to DBA-sup (3 days culture supernatant of DBA -cells with B 16 melanoma in the medium containing 0.2 U ml-' rlL.2) and the MAF activity was assayed and % cytolysis was calculated by the same method as in Figure   7 .
easily localise in situ in tumour tissue. Work is now in progress in our laboratory to determine the localisation of DBA+ and DBA-cells which are injected i.v. into B16-bearing mice.
As for the expression of Thyl antigens, both DBA+ and DBA-cells in the present study were found to be highly Thyl + and CD3 positive. Furthermore, both cell populations were also AGMI + (Table I) . Presumably, the majority of our DBA-effector cells derive from T cells, but NK cells are also present in this cell population. Yang et al. (1986) reported that LAK effector cells are clearly Thyl.2+ but Kalland et al. (1987) and Mule et al. (1987) showed that LAK cells are heterogenous at both the effector and precursor levels, and a major part of the LAK activity can be ascribed to IL-2-activated cells expressing surface markers associated with NK cells.
In conclusion, DBA- 
